Form 4: Troy Wilson exercises options and disposes shares at $45 under 10b5-1
Rhea-AI Filing Summary
Troy Edward Wilson, a director of Avidity Biosciences, Inc. (RNA), executed option exercises and share sales on 08/06/2025 under a previously adopted Rule 10b5-1 trading plan. He exercised 22,000 options at an exercise price of $12.03 and 7,500 options at $12.48, and sold shares at $45.00 per share pursuant to the plan.
Following the reported transactions the filing shows 69,425 shares held directly by the reporting person. The Form 4 also lists indirect beneficial ownership via several irrevocable trusts and a family trust, shown as 285,000, 285,000, 17,776, 17,776, 11,851, 11,851, and 13,711 shares. The filing states the 10b5-1 plan was adopted on December 4, 2024 and that all option shares were fully vested and exercisable at the time of exercise.
Positive
- Transactions executed under a Rule 10b5-1 plan, providing a preplanned framework for insider trades
- All option shares were fully vested and exercisable at the time of exercise, per the filing
Negative
- Multiple share sales at $45.00 on 08/06/2025 reduced the reporting person's direct holdings to 69,425 shares
- Large indirect holdings are held in several irrevocable trusts and a family trust, which may complicate consolidated ownership analysis
Insights
TL;DR Insider exercised vested options and sold shares under a 10b5-1 plan; direct holdings remain material.
The Form 4 reports option exercises of 22,000 and 7,500 shares at exercise prices of $12.03 and $12.48, respectively, with concurrent sales at $45.00 per share executed under a 10b5-1 plan adopted on 12/04/2024. The disclosure shows 69,425 shares held directly after the transactions and multiple blocks held indirectly via irrevocable and family trusts. This is a routine, preplanned liquidity event rather than an unplanned sale; it provides clear, itemized post-transaction ownership figures for investor review.
TL;DR Transactions were prearranged under a 10b5-1 plan and the filing confirms vesting status and trust-held indirect ownership.
The filing explicitly states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2024, and that the option shares were fully vested and exercisable when exercised. The Form 4 also discloses several sizable indirect holdings held in named irrevocable trusts and a family trust, with the specific share counts listed. From a governance standpoint, the filing meets Section 16 transparency requirements by documenting the plan, exercise prices, sale price, and post-transaction beneficial ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | -- |
| Exercise | Common Stock | 22,000 | $12.03 | $265K |
| Sale | Common Stock | 22,000 | $45.00 | $990K |
| Exercise | Common Stock | 7,500 | $12.48 | $94K |
| Sale | Common Stock | 7,500 | $45.00 | $338K |
| Sale | Common Stock | 15,000 | $45.00 | $675K |
| Sale | Common Stock | 15,000 | $45.00 | $675K |
| Sale | Common Stock | 17,777 | $45.00 | $800K |
| Sale | Common Stock | 17,777 | $45.00 | $800K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. All shares of common stock subject to this option were fully vested and exercisable as of the date of execution of this option by Reporting Person.
FAQ
What trades did the Avidity (RNA) insider report on the Form 4?
Was the insider trading done under a trading plan for Avidity (RNA)?
Does the Form 4 disclose indirect ownership for Avidity (RNA)?
